Evidence map›Paper›PMID 31538322›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2020

Quantitative

Federico Caobelli, Martin Braun, Philip Haaf, Damian Wild, Michael J Zellweger

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 68 citations in OpenAlex.

  1. Semi-quantitative evaluation of early phaseAnnals of nuclear medicine · 2026
    Article
  2. Early timepointEJNMMI research · 2026
    Article
  3. Article
  4. Quantitative evaluation ofAnnals of nuclear medicine · 2026
    Article
  5. Article
  6. Effects of tafamidis on serial [European journal of nuclear medicine and molecular imaging · 2025
    Article
  7. Clinical significance of quantitative assessment of right ventricular amyloid burden with [European journal of nuclear medicine and molecular imaging · 2025
    Article
  8. Review
  9. Collection on molecular imaging in cardiac amyloidosis.European journal of nuclear medicine and molecular imaging · 2024
    Article
  10. Transthyretin amyloid cardiomyopathy disease burden quantified usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  11. Cardiac Amyloid Quantification UsingJACC. Cardiovascular imaging · 2023
    Article
  12. Cardiac DPD-uptake time dependency in ATTR patients verified by quantitative SPECT/CT and semiquantitative planar parameters.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  13. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  14. Review
  15. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  16. Quantifying the burden of cardiac amyloid: The future is about numbers!Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  17. QuantitativeJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  18. Radiology · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Federico CaobelliNuclear Medicine Department, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. Federico.caobelli@usb.ch.
Martin BraunNuclear Medicine Department, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Philip HaafCardiology Department, University Hospital Basel, University of Basel, Basel, Switzerland.
Damian WildNuclear Medicine Department, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Michael J ZellwegerCardiology Department, University Hospital Basel, University of Basel, Basel, Switzerland.
University of Basel · CHUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhile a visual interpretation of

methodsin this retrospective study, consecutive patients underwent a

resultsThirteen patients were included. CA was confirmed in 8 and rejected in 5. Myocardial SUVmax and SUVpeak showed a fairly strong correlation with Perugini score (both ρ = .71, P = .006). Same held true for to-bone normalized values (both ρ = .75, P = .003). There was a great degree of overlap for quantitative values in patients with Perugini score 2 and 3.

conclusionQuantitative

Indexed as

Single Photon Emission Computed Tomography Computed TomographyAgedAged, 80 and overAmyloid Neuropathies, FamilialCardiomyopathiesDiphosphonatesFeasibility StudiesFemaleHumansMaleMiddle AgedOrganotechnetium CompoundsRadiopharmaceuticalsRetrospective StudiesWhole Body ImagingDiphosphonatesOrganotechnetium CompoundsRadiopharmaceuticalstechnetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid99mTc-DPD SPECT/CTATTR cardiac amyloidosisBone scanMetabolic disease

Identifiers

PMID31538322
OpenAlexW2973456003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.